Melatonin for Delirium Reduction, Resolution And Mitigation of Abnormal Arousal (MelaDRRAMAA)
Melatonin for Delirium Reduction, Resolution And Mitigation of Abnormal Arousal (MelaDRRAMAA): a double blinded placebo-controlled randomised trial of Melatonin 5mg nightly for 5 nights for the reduction of severity of delirium in older adult medical inpatients
Royal Melbourne Hospital
120 participants
Mar 11, 2021
Interventional
Conditions
Summary
Delirium is the sudden onset of confusion or hallucinations, due to an illness or medication. It affects the elderly particularly, and is both distressing to the sufferer and their carers, as well as causing death, disability and institutionalisation. Melatonin is a naturally occurring hormone in the human brain important in sleep. Sleep is disturbed in delirium, and studies have shown melatonin can prevent delirium. This study aims to determine whether Melatonin 5mg in oral capsules given nightly for 5 nights can treat and cure delirium that has developed in older patients in hospital.
Eligibility
Inclusion Criteria2
- Diagnosis of delirium (regardless of cause)
- Inpatient of the Royal Melbourne Hospital
Exclusion Criteria8
- exclusively hypoactive delirium,
- recent stroke (<14 days),
- sensory impairment or dysphasia or language such that not evaluable,
- planned for surgery,
- prognosis <7days,
- severe hepatic failure
- allergy or intolerance to melatonin or excipients.
- Treated with Melatonin or melatonin agonists within 24 hours prior to enrolment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Melatonin 5mg oral capsule nightly for 5 days administered directly by hospital nursing staff.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12619000034134